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leavage of amyloid precursor protein (APP) by the
Alzheimer’s 
 
 
 
-secretase (BACE1) is a key step in
generating amyloid 
 
 
 
-peptide, the main component
of amyloid plaques. Here we report evidence that heparan
sulfate (HS) interacts with 
 
 
 
-site APP-cleaving enzyme
(BACE) 1 and regulates its cleavage of APP. We show that
HS and heparin interact directly with BACE1 and inhibit in
vitro processing of peptide and APP substrates. Inhibitory
activity is dependent on saccharide size and speciﬁc
 
structural characteristics, and the mechanism of action
C
 
involves blocking access of substrate to the active site. In
cellular assays, HS speciﬁcally inhibits BACE1 cleavage of
 
APP but not alternative cleavage by 
 
 
 
-secretase. Endogenous
HS immunoprecipitates with BACE1 and colocalizes with
BACE1 in the Golgi complex and at the cell surface, two of
its putative sites of action. Furthermore, inhibition of cellular
HS synthesis results in enhanced BACE1 activity. Our
ﬁndings identify HS as a natural regulator of BACE1 and
suggest a novel mechanism for control of APP processing.
 
Introduction
 
A characteristic feature of Alzheimer’s disease (AD) is brain
deposits of aggregated amyloid 
 
 
 
-peptide (A
 
 
 
), which is
considered by many as central to the pathogenesis of AD.
A
 
 
 
 is a predominantly 40–42–amino acid peptide produced
from amyloid precursor protein (APP) by sequential pro-
teolytic processing at the NH
 
2
 
 and COOH termini of the
A
 
 
 
 domain (Howlett et al., 2000). After synthesis and post-
translational modifications, a proportion of APP molecules
are proteolytically cleaved by secretases in the Golgi complex,
cell surface, and endosomal–lysosomal system to yield A
 
 
 
 or
alternative cleavage products (Hendriksen et al., 2002).
Cleavage of APP by the recently identified aspartic protease
 
 
 
-secretase, also known as 
 
 
 
-site APP-cleaving enzyme
(BACE) 1, Asp-2, and memapsin-2 (Hussain et al., 1999;
Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin
et al., 2000), generates a soluble NH
 
2
 
-terminal fragment
(sAPP
 
 
 
) and a membrane-bound COOH-terminal frag-
ment (C99; see Fig. 1 A). Cleavage of the latter by an addi-
tional protease (
 
 
 
-secretase) produces A
 
 
 
 (Sisodia et al.,
2001). Inhibition of BACE1 has therefore emerged as a key
target for therapeutic intervention in AD (Howlett et al.,
2000; Hendriksen et al., 2002).
A number of A
 
 
 
-associated molecules have been identified
in tangles and senile plaques, including inflammatory proteins,
apolipoproteins, and heparan sulfate proteoglycans (HSPGs;
Verbeek et al., 1998). HSPGs play important roles in amyloid-
ogenesis through interactions with various proteins. They
are associated with the earliest stages of the formation of
amyloid plaques (Snow et al., 1994); they colocalize with A
 
 
 
in neuritic plaques, cerebrovascular amyloid, and neuro-
fibrillary tangles (Snow et al., 1990; Su et al., 1992); and
they promote A
 
 
 
 aggregation (McLaurin et al., 1999). Both
heparan sulfate (HS) and heparin (a highly sulfated structural
analogue of HS) bind fibrillar amyloid protein (Watson et
al., 1997; Lindahl et al., 1999) and enhance fibril formation
and stability (Castillo et al., 1997). Previous studies indi-
cated that low molecular weight heparin saccharides inhibited
APP secretion (Leveugle et al., 1998), prompting us to inves-
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tigate in more detail a potential role for cellular HS in
APP metabolism. We report for the first time that HS in-
teracts directly with BACE1 and regulates its activity. Our
findings identify HS as a natural regulator of BACE1 and
point to a novel mechanism for cellular modulation of
APP processing.
 
Results
 
HS and heparin inhibit BACE1
 
Using a peptide cleavage FRET assay, we found that both
HS and heparin inhibited BACE1 activity at its pH opti-
mum of 4.5 (Fig. 1 B). A maximal level of inhibition of
 
 
 
50–60% was observed in the presence of bovine lung hep-
arin (BLH) with an IC
 
50
 
 of 
 
 
 
1–2 
 
 
 
g/ml (
 
 
 
100 nM). Por-
cine mucosal and bovine mucosal heparins exhibited similar
activities (unpublished data). Porcine mucosal HS (PMHS)
and HS purified from a neuroblastoma cell line (N1e) both
displayed inhibitory activity (Fig. 1 B; IC
 
50
 
 
 
 
 
 10 
 
 
 
g/ml;
 
 
 
400 nM), but required higher concentrations to achieve
maximal inhibition (not depicted). The inhibitory activity
was specific for HS-type polysaccharides because the sulfated
galactosaminoglycan, dermatan sulfate (DS), was essentially
inactive (Fig. 1 B), and chondroitin sulfate inhibited only
weakly (
 
 
 
20% at 10–30 
 
 
 
g/ml) and did not inhibit at
higher doses (not depicted). We observed similar inhibitory
 
activities of BLH and PMHS in the presence of physiologi-
cal concentrations of NaCl (unpublished data), indicating
that these effects are not due to nonspecific electrostatic in-
teractions at the low ionic strength of the acetate buffer. We
also observed that BACE1 was active at neutral pH (7.0) in
the FRET peptide assay, although its activity was 
 
 
 
60-fold
lower than at its optima of pH 4.5 (unpublished data). In
addition, we examined the possibility that HS might en-
hance BACE1 activity under appropriate conditions, in par-
ticular at lower concentrations. However, apart from a slight
increase in activity at low concentrations in some assays
(
 
 
 
5–10% at 10–100 ng/ml; Fig. 1 B), we did not observe
any significant enhancement of BACE1 activity.
We confirmed the ability of heparin/HS to inhibit
BACE1 activity with an assay using full-length APP sub-
strate. Western blot analyses of cleavage of recombinant
APP to produce the COOH-terminal fragment designated
C99 (Fig. 1 A) demonstrated that both BLH and PMHS
strongly inhibit BACE1 activity at both pH 7.0 (Fig. 2, C
and D) and pH 4.5 (Fig. 2, E and F). In clear contrast to
the peptide assay, maximal inhibition of 
 
 
 
90–100% was
achieved. IC
 
50
 
 values of 1–2 
 
 
 
g/ml (
 
 
 
100 nM) for BLH
and 
 
 
 
5 
 
 
 
g/ml (
 
 
 
200 nM) for PMHS were comparable to
those observed in the peptide assay. Again, we obtained no
evidence for enhancement of BACE1 activity by HS or
heparin in these assays.
Figure 1. Heparan sulfates inhibit BACE1 cleavage 
of APP. (A) Schematic showing the structure of APP 
and the principal products generated by the action 
of  -,  -, and  -secretases. (B) BACE1 activity at pH 
4.5 was measured using an in vitro assay with a FRET 
peptide corresponding to the Swedish mutant  -cleavage 
site. Dose–response curves for BLH ( ), PMHS ( ), 
N1e neuroblastoma cell HS ( ), and DS ( ). Data are 
mean   SD (n   3). (C) BACE1 activity was also mea-
sured using an in vitro assay with authentic full-length 
APP substrate, pH 7. Dose responses to BLH, PMHS, 
and DS were assessed by Western blot detection of 
C99. (D) Graphical analysis of data derived by den-
sitometry of C99 bands from C for BLH ( ) and PMHS 
( ); data are mean   SD (n   2). (E and F) The same 
assay as in C and D but at pH 4.5.T
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BACE1 is a heparin-binding protein
 
Using heparin affinity chromatography, we determined that
the 10–amino acid FRET peptide does not bind to heparin at
physiological ionic strength at pH 4.5 or 7.0 (unpublished
data), suggesting that inhibition requires a direct interaction of
HS with BACE1. To address this question, we subjected
BACE1-Fc fusion protein to heparin affinity chromatography.
The majority of the protein (
 
 
 
60%) bound tightly to the col-
umn at pH 7.0, eluting as a peak requiring 
 
 
 
1.2 M NaCl for
elution (Fig. 2 A, peak A). Peak A contained 87% of the total
BACE1 activity and displayed a high specific activity (4.7 U/
 
 
 
g)
compared with the remainder of the protein that eluted at
 
 
 
0.15 M NaCl (Fig. 2 A, peak B) with low specific activity
(0.8 U/
 
 
 
g). Peak B’s material contained some copurifying HS,
as determined by dot blotting with an anti-HS antibody 10E4
(unpublished data), and this may explain its reduced activity.
Binding was specific to BACE1 because Fc does not bind hep-
arin (Powell et al., 2002). BACE1 also bound to heparin at pH
4.5 (the pH optima of BACE1) although with reduced affinity
(elution at 
 
 
 
0.4 M NaCl; Fig. 2 B). We also determined the
ability of BACE1 to interact with immobilized heparin using a
surface plasmon resonance biosensor. BACE1 bound to hepa-
rin in a dose-dependent manner at both pH 7.0 (Fig. 2 C) and
pH 4.5 (Fig. 2 D). The extent of binding at pH 4.5 was
 
 
 
25% lower than at pH 7.0, supporting the above data that
the interaction is weaker but still significant at the acidic pH.
To confirm that BACE1 also binds HS, we used an affin-
ity filter binding assay. Metabolically radiolabeled HS from
N1e neuroblastoma cells was eluted from nitrocellulose-
bound BACE1 using stepwise salt washes (0.15–2.0 M
NaCl). Essentially, all the HS chains bound to BACE1 and
eluted predominantly at 0.3–0.75 M NaCl (Fig. 2 E). The
spread of binding fractions is typical for HS in these assays,
reflecting the structural heterogeneity of HS polysaccha-
rides in comparison with heparin. These results demon-
strate that biologically active BACE1 interacts directly with
HS and heparin, and displays a high relative affinity for
these polysaccharides.
 
BACE1 inhibition depends on specific HS structures
 
To establish whether inhibition of BACE1 by heparin/HS is
dependent on saccharide size, we examined the activity of
various size-defined heparins in the peptide cleavage assay
(Fig. 3, A and B). Inhibition was clearly dependent on sac-
charide fragment length, with no inhibitory activity in frag-
ments of 
 
 
 
10 monosaccharide units (10mer; Fig. 3 A). The
level of inhibitory activity increased with increasing frag-
ment length, and 
 
 
 
24mers or larger displayed activity
equivalent to full-length heparin (Fig. 3 B). Sized fragments
from PMHS were also examined; 
 
 
 
14mers or larger were
required for significant inhibition of BACE1 (unpublished
data). This difference is probably due to the fact that these
Figure 2. BACE1 interacts directly with heparin 
and HS. (A) Elution profile of BACE1-Fc from a 
heparin affinity column with an NaCl gradient 
(dashed-dotted line) at pH 7. (B) The same as in A 
but at pH 4.5. (C) Surface plasmon resonance bio-
sensor binding profiles of the interaction of BACE1 
at different concentrations with immobilized 
heparin at pH 7.0. Concentrations were 100 (solid 
line), 50 (dotted line), 25 (black dashed line) and 
10  g/ml (gray dashed line). (D) The same as in C 
but at pH 4.5. (E) Affinity profile of 
3H-labeled neuro-
blastoma HS (from N1e cells) from BACE1 protein 
immobilized in a filter binding assay (elution with 
a stepwise NaCl gradient). Data are mean   SD 
(n = 3). (F) Inhibition of biosensor binding of BACE1 
(25  g/ml) to immobilized heparin, pH 7.0, by 
chemically modified heparins (25  g/ml). Binding 
curves (from top): no inhibitor (solid line), 6-O-
desulfated heparin (dash, single dot), unmodified 
BLH (dashed), oversulfated heparin (dotted), and 
N-acetylated heparin (dash, double dot). (arrow-
heads) Return to buffer alone; dissociation phase.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
100 The Journal of Cell Biology 
 
|
 
 
 
Volume 163, Number 1, 2003
 
saccharides often contain lower sulfated flanking disaccha-
rides (Guimond and Turnbull, 1999).
Next, we evaluated whether inhibition of BACE1 is de-
pendent on specific structural features of heparin/HS by
testing selectively chemically modified heparins in the pep-
tide cleavage assay (Fig. 3 C). Removal of 
 
 
 
80% of 6-O-sul-
fates dramatically reduced inhibitory potency, whereas com-
plete removal of 2-O-sulfates resulted in only a moderate
reduction in activity compared with heparin. Over-sulfation
of heparin also reduced its inhibitory activity, providing fur-
ther evidence that potency is not related simply to sulfation
level, and supporting the data indicating that other sulfated
glycosaminoglycans have low potency (Fig. 1). Remarkably,
removal of N-sulfate groups and their replacement by
N-acetyl groups resulted in a substantial increase in potency
(approximately fivefold) compared with heparin (IC
 
50
 
 
 
  
 
0.2
 
 
 
g/ml; 
 
 
 
16 nM). In contrast, complete desulfation (re-
moval of all N- and O-sulfates) abolishes all activity (unpub-
lished data). Thus, activity is dependent on 6-O-sulfate
groups, is only partially dependent on 2-O-sulfate groups,
and is enhanced by the presence of additional N-acetylated
glucosamine residues. We obtained no evidence for any sig-
nificant enhancement (
 
 
 
5–10%) of BACE1 activity with
any of these modified polysaccharides, even at low concen-
trations (
 
 
 
1–100 ng/ml; Fig. 3 C).
The differential activities of chemically modified heparins
were confirmed with APP as substrate and were in complete
agreement with the peptide substrate data (Fig. 3 D). We
also observed that the relative inhibitory activities of these
compounds correlated directly with their differing abilities to
act as soluble inhibitors of the BACE1–heparin interaction
using surface plasmon resonance. N-acetylated heparin was
more potent and 6-O-desulfated heparin less potent than pa-
rental BLH (Fig. 2 F). Together, these experiments clearly
show that saccharide size and sulfation patterns are critical
for the inhibitory activity of these molecules, and we ob-
tained no evidence that any variant structures could enhance
BACE1 activity. Furthermore, the data indicate that inhibi-
tory potency correlates directly with ability to bind BACE1.
 
Cellular BACE1 is inhibited by heparin/HS
 
Next, we addressed the question of whether heparin/HS also
inhibits BACE1 activity in cells by undertaking Western blot
analyses of media from SHSY5Y neuroblastoma cells express-
ing APP with the Swedish mutation (SHswAPP). Treatment
with either BLH or PMHS inhibited generation of the
BACE1 cleavage product sAPP
 
 
 
, whereas DS had no effect
(Fig. 4 A, left panels; and Fig. 4 B, dose–response curves). In
addition, chemically modified heparins produced levels of
BACE1 inhibition, relative to heparin, identical to those ob-
served in the peptide and APP in vitro cleavage assays. Impor-
tantly, the enhanced potency of N-acetylated heparin was
confirmed. In contrast, there was no effect on generation of
the 
 
 
 
-secretase cleavage product sAPP
 
 
 
 (Fig. 4 A, right pan-
els), showing that inhibition was specific for BACE1. Similar
results were obtained with HEK293T cells expressing APP
with the Swedish mutatation (SWDC1cells; unpublished
data). We confirmed these effects on cellular BACE1 activity
by measurement of generation of A
 
 
 
1-42
 
 peptide by SWDC1
cells using an ELISA assay. Treatment with BLH or PMHS
resulted in a dose-dependent inhibition of the levels of A
 
 
 
1-42
 
secreted into the medium, and the N-acetylated heparin was
again more potent than BLH (Fig. 4 C). Similar data on the
inhibition of A
 
 1-42 secretion were obtained using SHswAPP
cells (unpublished data). Furthermore, A 1-40 secretion was
also inhibited to an equivalent degree in both SWDC1 and
SHswAPP cells (unpublished data). Although the apparent
maximal level of BACE inhibition is higher, measured by
sAPP  levels (Fig. 4, A and B) compared with A 1-42 levels
(Fig. 4 C), the IC50 values were in good agreement in all cases
and were closely similar to those obtained in the in vitro ex-
periments (Figs. 1 and 3). Together, these results demon-
strate that HS added exogenously to cells selectively inhibits
BACE1 processing of APP, with no apparent effects on the
 -secretase or  -secretase processing events.
Endogenous HS interacts with and regulates BACE1
Next, we sought to determine whether BACE1 interacts with
endogenous HS in cells. HEK293T cells express HSPGs that
can be detected by Western blotting of cell lysates using an
anti-HS antibody (10E4), and their identity was confirmed by
susceptibility to heparitinase digestion (Fig. 5 A). We found
that HSPGs were coimmunoprecipitated with an anti-BACE1
antibody from cell lysates of both parental HEK cells and
HEK293T cells stably transfected with myc-tagged BACE1
Figure 3. Specific saccharide structures are required for inhibition 
of BACE1. Structural specificity of the inhibition of BACE1 by HS/
heparin was investigated using size-defined, and chemically modified, 
heparins in the FRET peptide cleavage assay, pH 4.5. (A and B) 
Dose–response curves of the inhibitory activity of size-defined 
fragments from BLH. (A) 8mer ( ), 12mer ( ), 20mer ( ), and 
full-length BLH ( ); (B) 10mer ( ), 16mer ( ), 24mer ( ), and 
full-length BLH ( ). (C) Dose–response curves of the inhibitory 
activity of chemically modified BLH: 80% 6-O-desulfated (de6S;  ), 
2-O-desulfated (de2S;  ), de-N-sulfated/reN-acetylated (deNS;  ), 
oversulfated (OverS;  ), and parental BLH ( ). Data for A–C are 
mean   SD (n   3). (D) Inhibitory activity of the chemically modified 
heparins described in C measured using the APP substrate assay, 
pH 7, with Western blot detection of C99 product.T
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(HEK-BACE1; Fig. 5 A), indicating that BACE1 interacts
with endogenous HS and forms complexes. We also found
that BACE1 coimmunoprecipitated with HS when an anti-HS
antibody 10E4 was used (unpublished data). Quantitative
measurements using a CCD camera (see Materials and meth-
ods) indicated that only a proportion of HSPGs ( 10–20%)
were coimmunoprecipitated from cells expressing endogenous
BACE1 levels (parental HEK), whereas the amount coimmu-
noprecipitated increased in HEK-BACE1 cells, which overex-
press BACE1 (unpublished data). It was noteworthy that
BACE1 selectively immunoprecipitated only a fraction of the
total HSPGs expressed in the HEK cells. In particular, the
lower molecular mass HSPGs in the range 70–100 kD were
preferentially immunoprecipitated due to their interaction
with BACE1 protein. Specificity of the interaction was con-
firmed in three ways. First, we confirmed that the anti-BACE1
antibody was not binding nonspecifically to the HSPGs by
demonstrating that an anion exchange purified HSPG extract
devoid of BACE1 protein was not susceptible to immunopre-
cipitation (Fig. 5 B). Second, we showed that inclusion of hep-
arin (a selective inhibitor of HS–protein interactions) abolished
BACE1-mediated immunoprecipitation of HSPGs (Fig. 5 C).
Third, using a sensitive protein stain, we also confirmed that
BACE1 was the only protein immunoprecipitated in signifi-
cant quantity ( 95% of total protein) from the lysate, dis-
counting the possibility that a secondary protein was mediating
the HS–BACE1 interaction (unpublished data).
To identify the localization of these cellular BACE1–HS
complexes, we performed immunofluorescence microscopy
on HEK-BACE1 cells using antibodies specific for BACE1
and HS. myc-BACE1 was detected with an anti-myc anti-
body and was predominantly expressed intracellularly in the
Golgi complex, and on the cell surface (Fig. 6 A, top pan-
els). HS was expressed on the cell surface and also in the
Golgi complex, and merged images demonstrated its colo-
calization with BACE1 (Fig. 6 A, top panels). To rule out
the possibility that colocalization of BACE1 and HS was
due to overexpression of BACE1, we also examined their lo-
calization in non-BACE–transfected SHswAPP cells. As ob-
served for the HEK-BACE1 cells, HS was strongly ex-
pressed on the cell surface but also in the Golgi complex,
and colocalized with BACE1 (detected with a rabbit anti-
BACE1 antibody) (Fig. 6 A, bottom panels). Similar data
for BACE1 localization in SHswAPP cells were also ob-
tained with a mouse anti-BACE1 monoclonal antibody
(unpublished data). We also performed confocal immuno-
fluorescence analysis; the data clearly confirmed the colocal-
ization of HS and BACE1 at the cell surface and in the
Golgi complex in HEK-BACE1 cells (Fig. 6 B).
Golgi localization of both BACE1 and HS was confirmed
by colocalization with a known Golgi marker,  -COP pro-
tein (Fig. 6 C). Similar results for BACE1 in HEK-BACE1
cells were obtained using rabbit anti-BACE1 and chicken
anti-BACE1 polyclonal antibodies (unpublished data). Mark-
ers of late endosomal (Fig. 6 C, CD63) and recycling endo-
somal (CD71; not depicted) compartments were used to
confirm that BACE1 is also expressed at these sites. Similar
data were obtained with SHswAPP cells (unpublished data).
HS was not detected in endosomes with 10E4 antibody,
probably because this epitope is sensitive to partial degrada-
tion by heparanase in this compartment.
Overall, these results demonstrate that endogenous HS
colocalizes with BACE1 in at least two of the cellular sites (cell
surface and Golgi complex) identified as potential sites for
cleavage of APP substrate by BACE1. If endogenous HS plays
a role in restricting BACE1 activity, it might be expected that
Figure 4. Cleavage of APP by BACE1 in cells is inhibited 
by HS. The effects of addition of exogenous HS to cells on 
BACE1 activity was tested in cells expressing swAPP. 
(A) The levels of sAPP  and sAPP  cleavage products in 
the medium of SHswAPP exposed to different doses of 
HS/heparins (Fig. 3) were measured by Western blotting. 
(B) Graphical analysis of the of data derived by densitometry 
of bands from A. BLH ( ), PMHS ( ), de6S ( ), deNS ( ) 
and DS control ( ). (C) The levels of A 1-42 peptide in the 
medium of SWDC1 exposed to PMHS (white bar), BLH 
(black bar), and N-acetylated heparin (hatched bar) was 
measured by ELISA. Data are mean   SD (n   3).T
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reducing cellular HS levels could enhance BACE1 activity. To
explore this possibility, we examined the effect of chlorate
treatment on cellular BACE1 activity. Chlorate is a competi-
tive inhibitor of the formation of the sulfate donor (PAPS) re-
quired for sulfation in HS biosynthesis; chlorate treatment of
cells resulted in abolition of binding of 10E4 antibody to cells,
confirming the absence of the sulfated endogenous HS
epitope (unpublished data). Under these conditions, the pro-
duction of both A 1-42 and A 1-40 peptides was significantly
elevated (by  20 and 40%, respectively) in comparison with
control cells (Fig. 7, A and B), indicating that endogenous HS
is acting to restrict BACE1 activity in untreated cells. Elevated
BACE1 activity in the chlorate-treated cells (as measured by
A  levels) was susceptible to inhibition by exogenous heparin
with equivalent IC50 values to those seen in normal cells (Fig.
7, C and D). Moreover, the level of sAPP  is completely un-
affected by these treatments; however, sAPP  levels were ele-
vated by chlorate treatment, and could be inhibited in both
control and chlorate-treated cells by addition of exogenous
heparin (Fig. 7 E). These results indicate that elevated BACE1
activity was not due to secondary chlorate-induced alterations
in trafficking or rates of production of APP. In addition, treat-
ment of cells with a mixture of heparitinases (which remove
cell surface HS) results in a marked elevation of BACE1 activ-
ity (Fig. 7 F). Together, these results strongly support the view
that endogenous HS acts to restrict BACE activity.
Mechanism of HS inhibition of BACE1
To explore how exogenous heparin/HS can inhibit BACE1,
we examined the time course of binding and uptake of flu-
Figure 5. BACE1 interacts with endogenous HS in cells. 
The interaction of BACE1 with endogenous HS was examined using 
coimmunoprecipitation assays. (A) Western blot analyses were 
performed on cell lysates (20  l) from myc-BACE1–transfected 
(HEK-BACE) and parental HEK293T (HEK) cells, either with or 
without immunoprecipitation of BACE1 with a chicken anti-BACE1 
antibody (IP). Detection was achieved with a rabbit anti-BACE1 
antibody (for BACE1) and 10E4 antibody (for HS). myc-tagged 
BACE1 was identified by reprobing with an anti-myc antibody 
(not depicted). (black arrowhead) myc-tagged BACE1; (white arrow-
head) native BACE1; H’ase, heparitinase treated; NS, no sample 
(PBS); Ab, IP antibody only. (B) HSPGs from wild-type HEK 293T 
lysates were purified by DEAE anion exchange and subjected to 
Western blotting with or without immunoprecipitation as in A. 
The HEK lysate contained both HSPGs (top) and BACE1 (bottom), 
and both were immunoprecipitated by anti-BACE1. In contrast, 
the purified HSPG extract (DEAE), which did not contain BACE1 
(bottom) was not immunoprecipitated by an anti-BACE1 antibody. 
(C) Lysates from HEK293T cells were subjected to immunoprecipitation 
of BACE1 as in (A), in the presence or absence of 50  g/ml heparin 
(an inhibitor of HS–protein interactions).
Figure 6. BACE1 colocalizes with endogenous HS in cells. The 
colocalization of BACE1 with endogenous HS was examined using 
immunofluorescence microscopy. (A) Immunofluorescence double 
staining of HEK-BACE and SHSY5YswAPP cells was performed to 
detect HS (green; 10E4 antibody) and BACE1 (red; anti-myc tag for 
HEK-BACE1 or rabbit anti-BACE1 for SHSY5Y cells). Merged images 
show colocalization of BACE1 and HS predominantly at the cell 
surface and in the Golgi complex. (B) Confocal immunofluo-
rescence microscopy of HEK-BACE cells staining for HS (green; 
10E4) and BACE1 (red; rabbit anti-BACE1). (C) Immunofluorescence 
of HEK-BACE cells staining for HS (green; 10E4) or BACE1 (green, 
top panels; red bottom panels; goat anti-BACE1), and comparison 
with known markers of the Golgi complex (red;  -COP) or late 
endosomes (green; CD63). Bars, 10  m.T
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orescent-labeled heparin by SWDC1 cells. Using Alexa
488–heparin, we detected specific binding at the cell
surface within 30 min, strong uptake, and intracellular
clustering within 2 h. Internalized heparin clearly colocal-
ized with the endosomal marker CD-71 and, there was no
evidence of localization in the Golgi complex (unpublished
data). These data suggest that the inhibitory effects of ex-
ogenous heparin/HS are primarily exerted at the cell sur-
face and in endosomal compartments. Studies to deter-
mine the mechanism of action of heparin/HS on BACE1
were undertaken using fluorescence polarization to exam-
ine the binding of a rhodamine-labeled noncleavable pep-
tide substrate (R110) to BACE1. The R110 ligand binds
to free BACE1 at the substrate binding site, increasing the
polarization of light relative to unbound ligand. Binding of
a known competitive ligand (GW 642976A) at the active
site is detected as a decrease in polarization (due to dose-
dependent displacement of the R110 ligand) whether
added after or before preequilibration of R110 with
BACE1 (Fig. 8, A and C). In contrast, we observed that if
R110 is preequilibrated with BACE1, inhibition by BLH
or N-acetylated heparin was abolished (Fig. 8 B); inhibi-
tion was achieved if BLH or N-acetylated heparin were
preequilibrated with BACE1 (Fig. 8 D). No effect was ob-
served for a DS control under either conditions (Fig. 8, B
and D). These data suggest that HS acts to prevent entry of
the substrate to the active site, and, furthermore, that if the
ligand is prebound to BACE1, HS can effectively lock the
ligand into the active site.
Discussion
HS interacts with BACE1 and regulates APP cleavage
Our in vitro assay data demonstrate direct inhibition of
BACE1 cleavage of both peptide and full- length APP sub-
strates by heparin/HS polysaccharides (Fig. 1). Inhibition of
APP cleavage was confirmed in cell assays measuring forma-
tion of the BACE1 cleavage products sAPP  and A  (Fig.
4), and was specific for BACE1 because no effect on  -secre-
tase was evident (Fig. 4). Interestingly, our data differ from a
previous study in which heparin was shown to enhance the
levels of sAPP  secreted by cells (Leveugle et al., 1997). We
did not obtain any evidence for significant enhancement of
BACE1 activity by any heparin/HS structures. The most
likely explanation for these differences is that the previous
experiments involved a 24-h recovery period after heparin
treatment; hence, their data may reflect a transient rise in
BACE1 activity in response to withdrawal of inhibition.
Our fluorescence polarization data (Fig. 8) provided an
insight into the mechanism of action of HS. The data sug-
gested that the principal mechanism for inhibition involves
binding of HS to BACE1, probably at or near the active site
in a manner that blocks access of the substrate (Fig. 9). The
cocrystal structure of BACE with the peptide isoster ana-
logue OM99-2 reveals the existence of a hairpin loop cover-
ing the active site (Hong et al., 2000). This loop is common
to aspartyl proteases and is referred to as the flap. Our data
agree with the binding of HS occurring with the closed con-
formation of the active site. Confirmation of this possibility
Figure 7. Inhibition of endogenous HS synthesis or 
sulfation induce elevated levels of BACE1 activity. The 
effect of chlorate on the generation of BACE1 cleavage 
products of APP in SHswAPP cells was assessed by 
immunoassay of A 1-42 (A) and A 1-40 (B) peptides in the 
medium of cells with or without chlorate treatment (see 
Materials and methods). *, P   0.01 (t test). All data are 
mean   SD (n = 3). The heparin dose response of cells 
treated with (black bars) or without (white bars) chlorate 
was assessed, measuring A 1-42 (C) and A 1-40 (D) pep-
tides in medium by immunoassay (see Materials and 
methods). (E) SHswAPP cells were treated with 30 mM 
chlorate in the presence or absence of heparin (50  g/ml) 
for 12 h, and measurement of medium sAPP  and sAPP  
was performed as described in Fig. 4. (F) SHswAPP cells 
were treated with a mixture of heparitinases (see Materials 
and methods) to remove cell surface HS, and the levels of 
medium A 1-42 were measured by immunoassay. Chlorate 
or heparitinase treatments abolished binding of 10E4 
anti-HS antibody to cells (not depicted). T
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would require NMR and X-ray crystallography studies,
which are in progress. Although natural inhibitors of aspar-
tyl proteases are rare, another unusual inhibitor binding to
proteinase A has recently been reported (Li et al., 2000).
To the best of our knowledge the data presented here are
the first identification of a natural direct inhibitor of BACE1,
and the first description of BACE1 as a heparin/HS–binding
protein. It is well known that APP also interacts with heparin
(Multhaup et al., 1995; Clarris et al., 1997), and we have re-
cently determined that a subpopulation of neural HS chains
bind APP with high affinity (unpublished data). Thus, our
data demonstrate that HS can interact with both the protease
and its substrate. This suggests an additional mechanism of
inhibition of BACE1 in which HS could sequester APP away
from the active site (Fig. 9). It is noteworthy that much higher
levels of inhibition are apparent with authentic APP in com-
parison with peptide substrates. This suggests that binding of
HS to BACE1 alone is insufficient for maximal inhibition and
that binding of HS to APP may be an important component
of the inhibition of cleavage of authentic protein substrate.
Further studies are needed to identify the HS-binding site in
BACE1 and to isolate and fully characterize the cellular HS
structures responsible for interactions with BACE1. Surface
charge modeling of the published crystal structure of a  -secre-
tase dimer (Hong et al, 2000) reveals some strongly basic
regions as potential binding sites (unpublished data). It is
plausible that HS interacts with such sites to regulate substrate
access, although we cannot exclude the possibility of confor-
mational effects on the BACE1 protein that allosterically reg-
ulate the active site.
Structural determinants in HS for BACE1 inhibition
With respect to the HS structural specificity for BACE1 in-
hibition, inhibitory activity was present in heparin saccha-
rides of at least 10 monosaccharide units (Fig. 3). Over-sul-
fated heparin (which serves as a control for high charge)
and de–2O- or de–6-O-sulfated heparin have reduced po-
tency compared with heparin, whereas substitution of
N-sulfate with N-acetyl groups results in increased inhibi-
tory activity (Fig. 3 C). This argues strongly that inhibitory
activity is not simply a function of charge density but results
from a significant degree of specificity in the glycan struc-
tures. This view was supported by experiments on the abil-
ity of the modified heparins to inhibit binding of BACE1
to heparin (Fig. 1 F). The removal of iduronate 2-O-sulfate
or glucosamine 6-O-sulfate groups may impair molecular
interactions of HS with BACE1. In contrast, replacement
of N-sulfates with N-acetyl groups may increase inhibitory
activity due to enhanced interactions of the uncharged N-ace-
tyl function in the BACE1 binding site. However, there
is also evidence that conformations of both sugar rings (in
iduronate) and glycosidic linkages are altered upon various
structural modifications (Yates et al., 2000). Hence, subtle
conformational effects of altered substitution patterns may
also underlie differences in activity. Overall, it is clear that
there is a considerable degree of specificity in the size and
structural characteristics of HS saccharides competent to
inhibit BACE1 activity. This is important because there is
emerging evidence that cells dynamically regulate HS struc-
tures, e.g., during neurogenesis (Ford-Perriss et al., 2002).
Regulated synthesis of appropriate inhibitory HS struc-
tures, and modulation of their concentration levels at ap-
propriate subcellular sites, may provide neural cells with a
mechanism for modulating BACE1 processing of APP.
BACE1 interacts with endogenous cellular HS
We also addressed the crucial question of the ability of
BACE1 to bind endogenous HS in cells. HS was immuno-
precipitated by BACE1 from cell extracts (Fig. 5), which is
consistent with the direct in vitro interaction we have de-
Figure 8. Heparan sulfate blocks access of substrate to the 
BACE1 active site. Fluorescence polarization measurements 
were made using a noncleavable fluorescent ligand R110 
(see Materials and methods). Fluorescence polarization 
measures the binding or displacement of the fluorescent 
ligand by detecting changes in polarization. Dose responses 
are shown for a known competitive inhibitor (A and C; GW 
642976A) or polysaccharides (B and D; BLH,  , solid line; 
NAc heparin,  , dashed line; and DS,  ). BACE1 was 
equilibrated for 2 h with either R110 (A and B) or the 
inhibitor compounds (C and D), followed by a 6-h incubation 
to establish equilibrium. All data are mean   SD (n = 3).T
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scribed here (Fig. 2). The data indicated that selective cell-
associated HSPG species bind to BACE1; likely candidates
are syndecans or glypicans (see next paragraph), and the pre-
cise identity of these remain to be elucidated in future stud-
ies. BACE1 is thought to act on APP at several subcellular
sites including the Golgi complex, cell surface, and endo-
somes (Haass et al., 1995; Thinakaran et al., 1996; Perez et
al., 1999). Importantly, we have demonstrated here that
BACE1 colocalizes with HS in both the Golgi complex and
at the cell surface (Fig. 6), and that removal of endogenous
HS or inhibition of HS sulfation results in increased BACE1
activity (Fig. 7). These data provide strong evidence that
HS–BACE1 interactions are relevant in a cellular context,
and also that cellular HS acts to restrict the activity of
BACE1. We have not yet established colocalization of HS
with BACE1 in endosomes, but it is well known that HS is
present in endosomes during its trafficking to the lysosomes
for degradation (Yanagishita, 1992; Egeberg et al., 2001).
However, we have observed that exogenous heparin is taken
up and concentrated in the endosomes (unpublished data),
making this a likely site for the inhibitory action of exoge-
nous HS/heparin, in addition to the cell surface. Further-
more, we have shown that HS and heparin bind and inhibit
BACE1 under both neutral and acidic conditions (Figs. 1
and 2), indicating the potential for HS to modulate BACE1
activity at both the cell surface and in the acidic environ-
ment of endosomal compartments. Thus, HS is found at
known cellular sites of BACE1 activity, supporting the no-
tion that it has a potential physiological role in modulating
its function.
We suggest that transmembrane or GPI-linked HSPGs
(such as syndecan or glypican family members, respectively)
are likely candidates for regulation of BACE1 activity. Be-
cause both BACE1 and APP are also membrane-bound pro-
teins, HSPGs are ideally positioned to interact with, and
control, the activities and functions of these molecules (Fig.
9). HSPGs may also play an important role in modulating
the endocytic trafficking of APP and BACE from the cell
surface to endosomal compartments. Interestingly, a recent
study has indicated that access of  -secretase to APP, and
thus A  generation, may be determined by dynamic interac-
tions within lipid rafts (Ehehalt et al., 2003). Syndecan
HSPGs have been shown to associate with lipid rafts (Fuki
et al., 2000), and GPI-linked glypicans are also candidates
for such an association. It is tempting to speculate that these
HSPGs could participate in controlling the segregation of
APP and BACE in lipid rafts, which serves to regulate the
level of  -secretase cleavage (Ehehalt et al., 2003).
Potential role of HS in AD pathology
Our findings may also have significance for AD pathology
because they suggest that HS could play an important role in
regulating generation of the A  peptide. It is notable that HS
from the cerebral cortex of AD patients exhibits structural
differences in comparison with normal tissue (Lindahl et al.,
1995). Subtle, but functionally significant, HS structural dif-
ferences or the expression of region-specific HS species may
occur in AD brain tissue. In addition, there is evidence for
age-dependent changes in HS structure in human tissue
(Feyzi et al., 1998). Such age- and disease-related changes in
brain HS could alter its ability to modulate BACE1 activity,
and thus contribute to the production of elevated levels of A 
peptide. Interestingly, the activities of the size-defined and
chemically modified heparins show that variant structures
can differentially inhibit BACE1. Heparin oligosaccharides
have been shown to pass the blood–brain barrier (Leveugle et
al., 1998) and could also act by interfering with HS-stimu-
lated A  aggregation, as described for small molecule anionic
sulfonates and sulfates (Kisilevsky et al., 1995). Thus, com-
pounds based on HS saccharides have potential as novel
drugs for reducing both the generation of A  and its aggrega-
tion into amyloid plaques. It is striking that the most potent
inhibition of BACE1 was observed with N-acetylated hepa-
rin, which has  1,000-fold lower anticoagulant activity than
parental heparin (Guimond, S., personal communication).
Because anticoagulant activity is a major side effect of heparin
in novel clinical applications (Lever and Page, 2002), our
data indicate the potential for creation of “designer” heparin-
based drugs as BACE1 inhibitors.
In summary, we have identified a novel role for HS as a
regulator of BACE1 processing of APP, in which it acts by
direct binding to the aspartyl protease and interfering with
access of APP substrate to the active site. Our findings sug-
gest that endogenous cellular HS could play an in vivo role
Figure 9. Model for regulation of BACE1 processing of APP by 
HS. (A) Direct inhibition of BACE1: HS chains (linked gray oval 
shapes) interact directly with the protease BACE1 (red), preventing 
access of the substrate APP (blue) to the active site (red diagonal 
hatching), or alternatively through conformational effects that 
allosterically regulate the active site. Specific HS structural motifs 
(black ovals) probably mediate this inhibitory interaction. The level 
and concentration of active HS structural motifs expressed on HSPGs 
in relevant cell compartments where BACE1 acts on APP could 
modulate the level of A  generated. (B) Sequestration of APP: HS 
also contains binding sites for APP (white ovals), providing an 
additional mechanism of action in which HS sequesters APP away 
from BACE1. This mechanism is supported by the enhanced BACE1 
inhibitory action of HS with full-length versus peptide APP sub-
strates. In addition, some neural HS chains have high affinity 
APP-binding sites distinct from those for BACE1 (unpublished data). 
Subpopulations of HSPGs carrying HS chains with APP-binding sites 
could segregate APP from BACE1. (arrows)  -,  - (BACE1), and 
 -secretase cleavage sites.T
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in controlling BACE1 cleavage of APP, and thereby regulate
the levels of A  peptide generated. Targeting this interac-
tion may form the basis of a novel therapeutic strategy for
reducing A  production in the treatment of AD.
Materials and methods
Polysaccharides
Heparins, DS, and CS were purchased from Sigma-Aldrich; PMHS was a gift
from Organon. BLH and PMHS were purified by treatment with chondroitin-
ase ABC, DEAE anion exchange, and ethanol precipitation. Fluorescent-
labeled heparin was prepared by reacting AlexaFluor 488 carboxylic acid
succinimidyl ester (Molecular Probes) with BLH in saturated NaHCO3 buffer.
In vitro peptide cleavage assay
Reaction reagents were dispensed in triplicate in 384-well black assay
plates (Nunc) to give final assay concentrations of 10 nM BACE1, 5  M
FRET peptide substrate (GW 684854X; GlaxoSmithKline), 0.06% Triton
X-100, and 100 mM sodium acetate, pH 4.5. Recombinant BACE1 (resi-
dues 1–460) was expressed in HEK293T cells as an Fc fusion protein, and
purified by protein A affinity (provided by C. Plumpton, GlaxoSmithKline,
Stevenage, UK). The FRET peptide was based on a previously described
substrate with the Swedish mutation (Yan et al., 1999). The reaction was
performed in the dark (25 C, 60 min) and the plate was read using a Tecan
Ultra Fluorimeter (485/535 nm). A known statin BACE1 inhibitor (GW
642976A; GlaxoSmithKline) was used in control assays.
In vitro APP cleavage assay
APP was purified from HEK293T cells transfected with human wild-type
APP. Supernatant from lysed cells was purified using Q-Sepharose, Hepa-
rin Hi-Trap, Mono Q, and reactive yellow dye ligand binding as described
previously (Moir et al., 1992; de La Fourniere-Bessueille et al., 1997; Oh-
shita et al., 1998). Reactions were prepared with 50  M APP, 100 nM
BACE1, 0.06% Triton X-100, and 100 mM sodium acetate, pH 4.5 or 7.0,
and incubated (25 C, 1 h) before denaturation in sample buffer and SDS-
PAGE on 4–20% Tris-glycine gels (Invitrogen). Cleavage products were de-
tected by Western blotting using rabbit anti–APP-  (Zymed Laboratories);
this antibody recognizes a 22–amino acid COOH-terminal region se-
quence of human APP and detects C99/C89 BACE1 cleavage products (re-
solved as doublets in some experiments) as well as full-length APP. Only a
small proportion of the APP ( 5%) was cleaved under the conditions used.
Supersignal West Pico chemiluminescence reagents (Pierce Chemical Co.)
and BioMax film (Kodak) were used for Western blot detection. Quantita-
tion was achieved by densitometry and validated by additionally exposing
the blots on a CCD chemiluminescence camera system (Syngene) with a
wide dynamic range.
Binding assays
For heparin affinity chromatography, BACE1 in PBS was loaded onto a 5-ml
HPLC HiTrap Heparin column (Amersham Biosciences; flow rate 1 ml/min).
Unbound material was eluted (10 ml PBS) and bound material was eluted
with a 60-ml linear gradient of 0–2.0 M NaCl. Surface plasmon resonance
binding experiments were performed on a Biacore 2000 in HBS buffer (flow
rate 10  l/min; Amersham Biosciences). BLH was biotinylated and immobi-
lized on streptavidin-coated chips as described (Warner et al., 2002). For fil-
ter binding assays, 
3H-labeled HS was purified from the N1e neural cell as
described by Brickman et al. (1998). The HS was agitated (4 C, 12 h) with
25  g BACE1 and bound material was step eluted with NaCl in a filter bind-
ing assay as described previously (Brickman et al., 1998).
Chemically modified heparins
Chemically modified heparins were prepared as described previously
(Yates et al., 1996). Size-defined heparin saccharides were purified by par-
tial cleavage of BLH with heparitinase III followed by gel filtration as de-
scribed previously (Turnbull et al., 1999).
Cellular assays for BACE1 cleavage of APP
SHswAPP and SWDC1 were seeded in 96-well plates at 10
5 cells/ml and
left to attach (37 C, 12 h) before incubation with compounds (24 h). Media
were tested using A 1-42 (Innogenetics) or A 1-40 (Biosource International)
immunoassay kits; control experiments confirmed that the presence of
heparin/HS does not interfere with peptide detection in this assay. To as-
sess sAPP  and sAPP  levels, cells were exposed to test compounds as de-
scribed for the A  immunoassays. Media were run on 10% Tris-glycine
gels. The products were detected by Western blotting using antibodies
against sAPP  (G27; GlaxoSmithKline) or sAPP  (6E10; Signet Labs). Hep-
arin or HS did not affect cell viability in these assays, as measured by MTT
assay (Guimond and Turnbull, 1999). Cells were treated with 30 mM chlo-
rate as described previously (Guimond et al., 1993; 12-h pretreatment plus
one passage, with continuous treatment throughout the experiment). Both
cell lines exhibited slightly reduced growth but no evidence of apoptosis
under these conditions. Heparitinase treatment was also used to remove
endogenous cell surface HS. Cells were treated with 2.5 mU each of hep-
aritinases I, II, and III (Ibex) in 15 ml of media (12-h pretreatment plus one
passage, with continuous treatment throughout the experiment).
Cellular assays for BACE1–HS interactions
In colocalization studies HEK-BACE1, as described previously (Hussain et
al., 1999), or SHswAPP cells were grown on poly-L-lysine–coated cover-
slips, washed with PBS, fixed and permeabilized with ice-cold methanol,
rinsed in PBS, and blocked with 0.1% BSA in PBS (30 min). The slides
were incubated with primary antibodies (either singly or in tandem) for 1 h,
washed in PBS, incubated with relevant secondary antibodies (20 C, 1 h),
and mounted using Fluorsave (Calbiochem) on Superfrost slides (BDH-
Merck). HS was detected by an anti-HS antibody 10E4 (Seikagaku) and
Cy2-conjugated or rhodamine red-X–conjugated goat anti–mouse second-
ary antibodies (Jackson ImmunoResearch Laboratories). Native BACE1 was
detected with rabbit anti-BACE1 polyclonal (Biosource International),
mouse anti-BACE1 monoclonal (Chemicon International), or chicken anti-
BACE1 polyclonal (GlaxoSmithKline) and AlexaFluor 594, 488, or 568
secondary antibodies. myc-BACE1 was detected with FITC-conjugated
9E10 anti-myc secondary antibody (Santa Cruz Biotechnology, Inc.).
Markers used were antibodies against CD71, for recycling endosomes, and
CD63, for late endosomes (Neomarkers), and  -COP for Golgi complex
(Affinity BioReagents, Inc.). For standard immunofluorescence, the cells
were visualized using a microscope (DMBR; Leica), camera (ORCA;
Hamamatsu), and Open Lab software (Improvision). Confocal images were
taken with an Eclipse E600 (Nikon) and a Radiance 2000MP system (Bio-
Rad Laboratories) using LaserSharp 2000 software (Bio-Rad Laboratories).
For endogenous HS pull downs, lysates were prepared from HEK293T and
HEK-BACE1 cells in 50 mM Tris, pH 7.5 (with 150 mM NaCl, 100  M
benzamide, 10  M E64, 1  M pepstatin A, 100  M chymostatin, 1  M
1,10-phenanthrolin, 2 mM EDTA, and 2% [wt/vol] octyl- -glucoside), and
20  l was incubated with a chicken anti-BACE1 antibody for 1 h at 4 C. In
some cases, the lysates were treated with heparitinase I to specifically di-
gest HS chains before immunoprecipitation. The complexes were incu-
bated with protein A–Sepharose (Amersham Biosciences; 4 C, 30 min),
centrifuged (1,000 g, 1 min), and washed. Bound proteins were eluted
with sample buffer, heated (100 C, 5 min), and run on 4–20% Tris-glycine
gels. The products were detected by Western blotting using anti-HS (10E4),
anti-myc (9E10), and rabbit anti-BACE1 polyclonal antibodies. Protein
staining (detection sensitivity   5 ng) was performed using the SimplyBlue
Safestain (Invitrogen) microwave procedure.
Fluorescence polarization
Changes in fluorescence polarization upon binding of a rhodamine-
labeled peptide ligand (R110; GlaxoSmithKline) to BACE 1 were measured
using an LJL Analyst instrument. R110 corresponded to the FRET peptide
described in In vitro peptide cleavage assay but contained a noncleavable
statin group at the cleavage site.
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